Alkermes, Inc.: Depressive Disorder, Major trials
The registry lists 10 Depressive Disorder, Major studies with Alkermes, Inc. as lead sponsor. 1 are open to participants now and 8 have results posted.
Phase 1 1Phase 2 3Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderRecruitingNCT07901179Phase 2
- A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)TerminatedNCT03610048Phase 3Results posted
- A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)CompletedNCT03188185Phase 3Results posted
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyCompletedNCT02218008Phase 3Results posted
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyCompletedNCT02158546Phase 3Results posted
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyCompletedNCT02158533Phase 3Results posted
- A Long-Term Safety Study of ALKS 5461CompletedNCT02141399Phase 3Results posted
- A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)CompletedNCT02085135Phase 3Results posted
- A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedNCT01500200Phase 2Results posted
- ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDCompletedNCT01381107Phase 1/2